SYK and autoimmune disease: In this study, we evaluated the effects of three SYK inhibitors on hepatic IRI: GS-9973, R406, and Piceatannol, which have now been shown to have therapeutic promise in hematologic tumors and autoimmune diseases (Liu and Mamorska-Dyga 2017; Currie et al. 2014; Suljagic et al. 2010).